- On 12 September 2026, Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804) announced a related‑party acquisition of A1 Biochem USA Inc.
- Its step‑down subsidiary A1 Biochem Labs (India) Private Limited subscribed to 10,000 equity shares at USD 100 each, paying USD 1,000,000 for 100 % ownership.
- No governmental or regulatory approvals were required; the subscription was completed on 11 September 2026.
- The deal is classified as a related‑party transaction, but the promoters and promoter group have no interest and the purchase was made at arm’s length.
- The acquisition expands Aurobindo Pharma’s contract research and development (CR&D) capabilities in the United States, building on the A1 Biochem Group acquisition disclosed on 23 July 2026.
The subscription of USD 1,000,000 (~₹8. 4 crore) for 100% ownership of A1 Biochem USA Inc is a positive operational step that expands Aurobindo's contract research and development (CR&D) platform in the United States, following up on the larger July 23, 2026 acquisition. The transaction is completed at arm's length without promoter interest.
Sign in for impact outlook, horizons, comparables, and full intelligence analysis.
Forecast from comparable, historic events. Not investment advice.
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka